PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
253.38%
Net income growth above 1.5x CRK's 58.26%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
1.63%
Less D&A growth vs. CRK's 174.63%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
-50.59%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
-48.89%
Negative yoy SBC while CRK is 16.16%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-73.91%
Both reduce yoy usage, with CRK at -158.27%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
202.94%
AR growth well above CRK's 45.42%. Michael Burry would fear inflated sales or less stringent credit controls vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-150.00%
Both reduce yoy usage, with CRK at -98.58%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-97.87%
Both negative yoy, with CRK at -84.97%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-46.73%
Both yoy CFO lines are negative, with CRK at -89.65%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-13.03%
Both yoy lines negative, with CRK at -135.85%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
-637.50%
Negative yoy acquisition while CRK stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
714.29%
Purchases growth of 714.29% while CRK is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-84.42%
We reduce yoy sales while CRK is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
-32.12%
Both yoy lines negative, with CRK at -100.00%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-57.96%
Both yoy lines negative, with CRK at -503.97%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
5.88%
Debt repayment well below CRK's 100.00%. Michael Burry suspects heavier leverage risk or insufficient cash generation to keep pace.
-100.00%
Negative yoy issuance while CRK is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.